Henry Meds Company Overview & Business Model: What Patients Should Know

What Is Henry Meds and How Does the Business Model Work?

Henry Meds operates as a subscription telehealth company focused on metabolic health and weight management. Patients pay a flat monthly fee, complete an online intake form, and are matched with a licensed prescriber in their state. If clinically appropriate, that prescriber writes a prescription for a compounded GLP-1 analog, which is then filled by a partner compounding pharmacy and shipped directly to the patient.

The company does not accept commercial insurance or Medicare. Every transaction is cash-pay, which keeps administrative overhead low but places the full cost burden on the patient. This mirrors the broader trend in telehealth weight-loss startups: companies including Ro, Hims & Hers, and Form Health have all experimented with cash-pay or membership models, though the regulatory environment for compounded GLP-1s has shifted significantly since 2023.

The 503A vs. 503B Pharmacy Distinction

The FDA regulates compounding pharmacies under two frameworks. Section 503A pharmacies compound drugs for individual patients based on a valid prescription. Section 503B "outsourcing facilities" can produce larger batches without patient-specific prescriptions, are subject to FDA inspection, and must follow current good manufacturing practice (cGMP) standards. FDA guidance on outsourcing facilities explains the distinction in detail.

Henry Meds has used both types of pharmacies at various points, and the clinical relevance matters: 503B facilities face more rigorous quality oversight than 503A pharmacies. Patients should ask directly which facility is filling their prescription and whether that facility has been inspected by the FDA without a Warning Letter. The FDA's list of registered outsourcing facilities is publicly searchable.

Revenue Model and Subscription Structure

The platform charges a recurring monthly fee rather than a per-prescription copay. This structure means Henry Meds earns revenue regardless of whether the patient achieves clinical outcomes. That incentive structure is worth understanding: the company's financial interest is in low churn, not necessarily in the same clinical benchmarks that define success in sponsored trials. Whether or not the compounded medication matches the efficacy of brand-name Wegovy or Zepbound depends on pharmacy quality, not on the telehealth platform itself.

Are Compounded GLP-1 Medications Clinically Effective?

The clinical evidence on GLP-1 receptor agonists for weight loss is strong, but every major trial used FDA-approved formulations, not compounded versions. The distinction is not trivial.

Evidence for Semaglutide 2.4 mg (Wegovy)

STEP-1 (N=1,961) showed that subcutaneous semaglutide 2.4 mg once weekly produced a mean body weight reduction of 14.9% at 68 weeks compared with 2.4% for placebo (P<0.001). Wilding et al., NEJM 2021 reported these results, which formed the basis of the FDA's 2021 approval of Wegovy. The SELECT cardiovascular outcomes trial (N=17,604) subsequently showed a 20% relative risk reduction in major adverse cardiovascular events with semaglutide 2.4 mg over a median 39.8 months. Lincoff et al., NEJM 2023 published this landmark finding.

Evidence for Tirzepatide (Zepbound)

SURMOUNT-1 (N=2,539) demonstrated that tirzepatide 15 mg produced a mean weight reduction of 20.9% at 72 weeks versus 3.1% placebo (P<0.001). Jastreboff et al., NEJM 2022 published this data. The FDA approved tirzepatide (Zepbound) for chronic weight management in November 2023.

What Compounding Changes

Compounded semaglutide is not the same drug product as Wegovy. The FDA has stated explicitly that compounded drugs are not FDA-approved and have not undergone review for safety, efficacy, or manufacturing quality. The agency's public statement on compounded semaglutide warns of risks including variable potency, sterility concerns, and mislabeled dosing instructions. No randomized controlled trial has assessed compounded semaglutide independently. Patients receiving compounded tirzepatide face the same evidentiary gap.

Some compounders add cyanocobalamin (vitamin B12) or other excipients to their semaglutide formulations. The clinical rationale for these additions is not established in the peer-reviewed literature, and the FDA has not evaluated their safety in combination.

Is Henry Meds Legit? Regulatory and Legal Standing

"Legit" has two separate meanings in this context: whether Henry Meds operates legally, and whether its clinical practices meet accepted standards of care.

Legal Operating Status

Henry Meds holds telehealth operating licenses across multiple states and employs or contracts with licensed prescribers. That baseline makes it a lawfully operating telehealth company. The more complex legal question involves its compounding pharmacy partners.

During the FDA-declared shortage period for semaglutide injection (which appeared on the FDA drug shortage database as active from 2022 through early 2025), 503A and 503B pharmacies were legally permitted to compound semaglutide under 21 USC 503A and 503B shortage provisions. In February 2025, the FDA announced it had resolved the semaglutide shortage, triggering a wind-down period during which compounding pharmacies were expected to cease bulk production of compounded semaglutide. The tirzepatide shortage resolution followed a similar timeline.

This shift materially affects Henry Meds and every similar platform. Prescribers writing for compounded GLP-1s after shortage resolution may be doing so outside the legal protection the shortage provision previously offered. Patients enrolled with Henry Meds should confirm whether their prescription is still legally fillable under current FDA policy and state pharmacy board rules.

Clinical Standards of Care

The Endocrine Society's 2023 clinical practice guideline on obesity pharmacotherapy recommends GLP-1 receptor agonists as first-line agents for patients with a BMI ≥30 or BMI ≥27 with at least one weight-related comorbidity. Garvey et al., J Clin Endocrinol Metab 2022 outline baseline evaluation requirements that include history, physical examination parameters, and cardiovascular risk assessment. A purely asynchronous intake form may not capture all of these parameters. Patients should verify that their assigned prescriber reviews actual clinical data, not just a self-reported questionnaire.

The American Association of Clinical Endocrinology (AACE) 2023 consensus statement on obesity management notes that any anti-obesity medication requires ongoing clinical monitoring, including blood pressure, heart rate, thyroid symptom screening, and GI adverse-event assessment. AACE consensus guidance establishes these touchpoints. A telehealth-only platform can fulfill these requirements through scheduled video visits and lab review, but patients should ask Henry Meds specifically how monitoring is structured and at what intervals.

How Much Does Henry Meds Cost?

Henry Meds publicly advertises plans starting at approximately $199 per month for compounded semaglutide, with compounded tirzepatide programs priced higher. These prices are meaningfully lower than the list prices for brand-name Wegovy (approximately $1,349 per month without insurance) or Zepbound (approximately $1,059 per month without insurance), based on current manufacturer pricing.

Cost Compared to Alternatives

The out-of-pocket cost advantage of compounded GLP-1 platforms is real, but it must be weighed against what patients are not getting. Brand-name Wegovy and Zepbound are covered under an increasing number of commercial insurance plans, and Novo Nordisk's savings card can reduce Wegovy costs to $0 per month for eligible commercially insured patients. The Novo Nordisk patient assistance page is not on our allow-list, so patients should confirm eligibility directly.

For uninsured patients, the cost comparison looks like this in approximate terms. Compounded semaglutide at Henry Meds runs roughly $199 to $349 monthly depending on dose tier. GoodRx prices for brand-name Wegovy in 2024 commonly exceed $1,000 per month without insurance. The gap is substantial. But the FDA's concern about compounded product quality means this is not a straightforward equivalence.

What Is Included in the Monthly Fee

The Henry Meds subscription typically covers the prescriber consultation, the compounded medication, and shipping. Routine labs, such as fasting glucose, HbA1c, and lipid panels that a comprehensive weight-management program should include, are generally not covered and must be obtained through a separate provider. The CDC guidance on obesity management notes that metabolic monitoring is a core component of weight-management care. Patients should budget for labs separately.

Henry Meds vs. Alternatives: Key Comparisons

Several telehealth platforms compete directly with Henry Meds on price, speed of access, and medication type. A factual comparison follows.

Henry Meds vs. Hims & Hers

Hims & Hers Weight was one of the first major telehealth brands to offer compounded semaglutide at competitive prices, with plans previously starting around $199 per month. Both companies use asynchronous prescribing models and rely on compounding pharmacy networks. The key operational differences are brand recognition, the breadth of other health services offered (Hims & Hers covers hair, skin, and sexual health), and the specific pharmacy partners used. Neither platform has published independent outcomes data on their patient cohorts.

Henry Meds vs. Form Health

Form Health takes a more clinician-heavy approach: patients are assigned a dedicated physician and registered dietitian, with regular video visits. Prices are higher, often exceeding $300 per month for the care team access alone, separate from medication costs. For patients who want more structured follow-up, Form Health's model aligns more closely with the monitoring cadence recommended by the Obesity Medicine Association's clinical treatment guidelines, which call for monthly visits during dose titration. Henry Meds does not appear to mandate that visit frequency.

Henry Meds vs. Ro (Body Program)

Ro's Body Program prescribes brand-name Wegovy when available and compounded semaglutide when not. This means Ro patients may, at times, receive an FDA-approved product rather than a compounded one, a clinically meaningful distinction. Ro also provides access to a health coach. Henry Meds is focused more narrowly on medication access and lower cost.

Selecting Based on Patient Profile

Patients with straightforward obesity (BMI ≥30, no major comorbidities, no prior GLP-1 exposure) and tight budget constraints may find Henry Meds' pricing acceptable. Patients with type 2 diabetes, cardiovascular disease, a history of pancreatitis, or personal or family history of medullary thyroid carcinoma require more careful prescriber evaluation than a brief intake form may provide. The FDA's Wegovy prescribing information lists these as contraindications or precautions and requires specific counseling. The FDA-approved Wegovy label should be reviewed by both prescriber and patient.

What Does Henry Meds Prescribe? Medications and Protocols

Henry Meds prescribers have access to several compounded formulations, though the exact menu changes as regulatory conditions shift.

Compounded Semaglutide

The standard offering has been compounded semaglutide injection, dosed weekly in a titration schedule that mirrors the Wegovy label: starting at 0.25 mg per week for four weeks, then advancing in increments toward a maintenance dose. Some Henry Meds-affiliated pharmacies have supplied semaglutide with added B12 or other ingredients, which changes the formulation from the trials and has not been independently evaluated for safety or efficacy. The FDA's MedWatch adverse event database has received reports of adverse events from compounded semaglutide, and the agency has issued multiple alerts.

Compounded Tirzepatide

After the FDA approved tirzepatide (Zepbound) for obesity in late 2023, and while a shortage declaration remained active, some platforms including Henry Meds added compounded tirzepatide to their formulary. SURMOUNT-2 (N=938, patients with type 2 diabetes) confirmed that tirzepatide 15 mg reduced body weight by 15.7% at 72 weeks. Garvey et al., NEJM 2023 published these findings. Again, no trial data exists on compounded tirzepatide specifically. The Zepbound prescribing information at FDA.gov details the approved titration schedule from 2.5 mg up to 15 mg weekly.

Other Medications in the Portfolio

Henry Meds also offers testosterone replacement therapy (TRT), thyroid medications, and other compounded hormones through its prescribing network. These fall outside the scope of this GLP-1 focused analysis but are relevant for patients considering the platform for metabolic health broadly.

Safety Profile and Monitoring Requirements

GLP-1 receptor agonists carry a recognized adverse-event profile that any prescribing platform must address systematically.

Gastrointestinal Adverse Events

In STEP-1, nausea affected 44% of semaglutide patients, vomiting affected 24%, and diarrhea affected 30% at some point during the trial, compared with 16%, 6%, and 16% respectively in the placebo group. Wilding et al., NEJM 2021 reported these rates. Most GI events were mild to moderate and resolved with continued treatment or dose reduction. Slow titration is the primary mitigation strategy, and any prescribing platform should have a protocol for patients who cannot tolerate dose escalation.

Thyroid and Pancreatitis Risk

The FDA requires a black-box warning on all GLP-1 receptor agonists regarding the risk of thyroid C-cell tumors, based on rodent studies, and the medications are contraindicated in patients with a personal or family history of medullary thyroid carcinoma (MTC) or Multiple Endocrine Neoplasia type 2 (MEN2). FDA Wegovy label, Section 5.1 details this warning. Pancreatitis has been reported, and the drug should be discontinued if pancreatitis is suspected. These contraindications require a clinical history that an asynchronous questionnaire may not reliably capture.

Cardiovascular Considerations

The SELECT trial demonstrated cardiovascular benefit, but the trial enrolled patients with pre-existing cardiovascular disease. For patients without established CVD, starting a GLP-1 agent at a telehealth platform without cardiometabolic baseline data is not aligned with Endocrine Society guideline recommendations that include assessment of cardiovascular risk before initiating pharmacotherapy.

Regulatory Outlook: What Comes Next for Compounding Platforms

The FDA's resolution of the semaglutide shortage in February 2025 set off a series of enforcement considerations for compounding platforms. The agency gave 503B outsourcing facilities a 60-day wind-down period and 503A pharmacies a 30-day period to stop bulk compounding. Platforms that continued to prescribe and dispense compounded semaglutide after these deadlines faced a more precarious legal position.

The FDA's compounding policy FAQ clarifies that after a shortage is resolved, the legal basis for outsized compounding volumes disappears. For patients currently enrolled with Henry Meds, the practical question is whether their prescription will continue to be fillable, and at what cost, as pharmacies adjust to post-shortage rules. Patients should not assume their current pricing and supply will remain stable through 2025.

The legal field may also shift based on ongoing litigation: several compounding pharmacy trade groups filed suit against the FDA's shortage resolution decision, and as of mid-2025, some courts had issued temporary injunctions that created state-level variability. Patients should check current FDA enforcement status directly at fda.gov for the latest guidance.

Patient Selection: Who May Benefit and Who Needs More Support

Not every patient seeking GLP-1 therapy is an appropriate candidate for a compounding-focused telehealth platform. The following criteria reflect evidence-based standards rather than platform marketing.

Candidates Who May Do Well

Patients with a BMI ≥30 (or ≥27 with documented hypertension, dyslipidemia, or obstructive sleep apnea), no prior GLP-1 exposure, no personal or family history of MTC or MEN2, no active pancreatitis history, no current pregnancy or planned pregnancy, and access to a primary care provider who can monitor labs and vital signs may find a cost-focused telehealth platform workable. The USPSTF 2018 recommendation on obesity interventions (Grade B) supports multicomponent interventions for adults with BMI ≥30.

Patients Who Need a Higher Level of Care

Type 2 diabetes, active cardiovascular disease, prior bariatric surgery, significant psychiatric history (GLP-1 agents have been linked to suicidal ideation in FDA's pharmacovigilance reviews), or age under 18 all indicate a need for a more supervised prescribing relationship. These patients should seek care through an obesity medicine specialist or endocrinologist who can review their full medical record.